Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

Monday, Bristol Myers Squibb & Co (NYSE:BMY) released data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating Krazati (adagrasib) in combination with cetuximab for previously treated ...

“Our preliminary data could shed light on why aggressive oral cancers often become resistant to cetuximab, one of the main FDA-approved targeted therapies,” Dr Chakraborty says. (Cetuximab is ...

For example, RAS mutations activate signalling pathways that are downstream of the epidermal growth factor receptor (EGFR), rendering EGFR inhibitors such as cetuximab inactive. Second ...

Globally recognised as a first-line standard of care, the public funding of ERBITUX®(cetuximab)[1] marks an important development for people living with left-sided RAS wild-type and BRAF wild ...

Associate Health Minister with responsibility for Pharmac David Seymour is pleased to see Pharmac continue to increase availability of medicines for ...

"Just as we learned that cetuximab (Erbitux) is inferior to cisplatin, we are now seeing that de-escalation based on our typical criteria is inferior to standard of care," she added. "The bar for ...

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...

Some that may be used are Avastin (bevacizumab), Erbitux (cetuximab), Vectibix (panitumumab), Zaltrap (ziv-aflibercept), Cyramza (ramucirumab), Stivarga (regorafenib), and Fruzaqla (fruquintinib).

Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel ...

Pfizer, Inc. gained FDA approval in December 2020 for BRAFTOVI (encorafenib) plus cetuximab to manage patients with brafv600e ...

Globally recognised as a first-line standard of care, the public funding of ERBITUX® (cetuximab) [1] marks an important development for people living with left-sided RAS wild-type and BRAF wild-type ...